Patents by Inventor Susan M. Freier

Susan M. Freier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9567587
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 14, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Sanjay Bhanot
  • Publication number: 20170037402
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 9, 2017
    Applicant: Regulus Therapeutics Inc.
    Inventors: Christine Esau, Bridget Gordon, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Publication number: 20170035798
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
    Type: Application
    Filed: March 21, 2016
    Publication date: February 9, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Chenguang Zhao, Brett P. Monia, Hong Zhang, Jeffrey R. Crosby, Andrew M. Siwkowski
  • Publication number: 20170037409
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof.
    Type: Application
    Filed: December 24, 2014
    Publication date: February 9, 2017
    Applicant: IONIS PHARMACEUTICALS, INC.
    Inventors: Susan M. FREIER, Mark J. GRAHAM, Rosanne M. CROOKE
  • Publication number: 20170037410
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Application
    Filed: April 1, 2015
    Publication date: February 9, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Tracy Cole, Holly Kordasiewicz, Susan M. Freier, Thomas P. Condon, Edward Wancewicz, Trisha Lockhart, Timothy Vickers, Priyam Singh
  • Publication number: 20170037403
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: August 11, 2016
    Publication date: February 9, 2017
    Applicant: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Patent number: 9546368
    Abstract: The present embodiments provide compounds and methods for reducing expression of Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1 (MALAT-1) RNA and/or protein in an animal. Such methods are useful for treating cancer, such as colon cancer, intestinal cancer, lung cancer (e.g. non-small cell lung cancer), liver cancer, and/or prostate cancer. In various aspects, the cancer is a primary cancer.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 17, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Eric G. Marcusson, Ssucheng J. Hsu, Robert A. MacLeod
  • Publication number: 20170002359
    Abstract: Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
    Type: Application
    Filed: August 28, 2014
    Publication date: January 5, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Huynh-Hoa Bui
  • Patent number: 9528108
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: December 27, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Publication number: 20160369275
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 22, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
  • Publication number: 20160369273
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Application
    Filed: April 29, 2016
    Publication date: December 22, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • Publication number: 20160362687
    Abstract: Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of fibrosis. Disclosed herein are methods for decreasing A1AT mRNA and protein expression and treating, ameliorating, preventing, slowing progression, or stopping progression of liver disease, such as, A1ATD associated liver disease, and pulmonary disease, such as, A1ATD associated pulmonary disease in an individual in need thereof. Methods for inhibiting A1AT mRNA and protein expression can also be used as a prophylactic treatment to prevent individuals at risk for developing a liver disease, such as, A1ATD associated liver disease and pulmonary disease, such as, A1ATD associated pulmonary disease.
    Type: Application
    Filed: April 13, 2016
    Publication date: December 15, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Michael L. McCaleb, Susan M. Freier, Shuling Guo
  • Patent number: 9518261
    Abstract: Disclosed herein are methods and compounds for inhibiting gene expression by inhibiting enhancer RNAs (eRNAs). Such methods and compounds are useful for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: December 13, 2016
    Assignees: Ionis Pharmaceuticals, Inc., The Regents of the University of California
    Inventors: Susan M. Freier, Christopher K. Glass, Michael G. Rosenfeld, Wenbo Li, Michael T. Lam
  • Publication number: 20160348104
    Abstract: Disclosed herein are antisense compounds and methods for decreasing STAT3 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate hyperproliferative diseases.
    Type: Application
    Filed: May 9, 2016
    Publication date: December 1, 2016
    Inventors: Eric E. Swayze, Susan M. Freier, Robert A. MacLeod, Youngsoo Kim
  • Patent number: 9487780
    Abstract: Provided are compounds comprising oligonucleotides complementary to a fibronectin transcript. Certain such compounds are useful for hybridizing to a fibronectin transcript, including but not limited to a fibronectin transcript in a cell. Such hybridization results in modulation of splicing of the fibronectin transcript. Such compounds are used to treat one or more symptoms associated with fibrosis. Such compounds are used to treat one or more symptoms associated with renal fibrosis.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: November 8, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Frank Rigo, Mark Dockrell, Felicia Heidibrecht
  • Publication number: 20160312217
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: January 25, 2016
    Publication date: October 27, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 9476051
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: October 25, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Thomas P. Condon, Ravi Jain, Richard Alan Smith, Don W. Cleveland
  • Publication number: 20160304877
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a DMPK mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preferentially reducing CUGexp DMPK RNA, reducing myotonia or reducing spliceopathy in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate type 1 myotonic dystrophy, or a symptom thereof.
    Type: Application
    Filed: August 11, 2014
    Publication date: October 20, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Sanjay K. Pandey, Robert A. MacLeod, C. Frank Bennett, Susan M. Freier
  • Patent number: 9447412
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: September 20, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: Bridget Gordon, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Eric E. Swayze, Ravi Jain, Balkrishen Bhat
  • Patent number: 9447413
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: September 20, 2016
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey